The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. (Q35208586)

7 August 2017

1 reference

title

The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. (English)

1 reference

7 August 2017

Fiona McLaughlin

1

1 reference

7 August 2017

Paul Finn

series ordinal

2

1 reference

7 August 2017

Nicholas B La Thangue

series ordinal

3

1 reference

7 August 2017

publication date

1 September 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

8

1 reference

7 August 2017

issue

17

1 reference

7 August 2017

page(s)

793-802

1 reference

CDK inhibitors: positive and negative regulators of G1-phase progression

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

The regulation of E2F by pRB-family proteins

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

The DNA damage response: putting checkpoints in perspective

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

DNA double-strand breaks: signaling, repair and the cancer connection

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

E2F and cell cycle control: a double-edged sword

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

The cell cycle and drug discovery: the promise and the hope

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Translating basic cancer research into new cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Modulating cell cycle: current applications and prospects for future drug development

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

1 reference

7 January 2021

Mitotic and G 2 Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

DNA damage-induced activation of p53 by the checkpoint kinase Chk2

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Chk2 activates E2F-1 in response to DNA damage

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

CHK2 kinase--a busy messenger.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Histone acetylases and deacetylases in cell proliferation

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

The language of covalent histone modifications

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Translating the Histone Code

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Perspectives for cancer therapies with cdk2 inhibitors

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Identification of E2F-1/Cyclin A antagonists.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

The human histone deacetylase family

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Cell cycle-dependent recruitment of HDAC-1 correlates with deacetylation of histone H4 on an Rb-E2F target promoter

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Role of the histone deacetylase complex in acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity

1 reference

https://api.crossref.org/works/10.1016/S1359-6446(03)02792-2

7 January 2021

10.1016/S1359-6446(03)02792-2

Identifiers

DOI

1 reference

7 August 2017

1 reference